Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins.
Animals
Antibodies, Monoclonal
/ pharmacology
Cell Adhesion
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Collagen Type I
/ metabolism
Gangliosides
/ immunology
Humans
Integrin beta1
/ metabolism
Integrins
/ metabolism
Mass Spectrometry
Melanoma
/ pathology
Membrane Microdomains
/ metabolism
Mice
Phenotype
Phosphotyrosine
/ metabolism
Signal Transduction
/ drug effects
GEM/rafts
cancer-associated antigen
ganglioside
integrin
melanoma
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
30
10
2021
revised:
12
12
2021
accepted:
28
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
4
2
2022
Statut:
epublish
Résumé
Gangliosides have been considered to modulate cell signals in the microdomain of the cell membrane, lipid/rafts, or glycolipid-enriched microdomain/rafts (GEM/rafts). In particular, cancer-associated gangliosides were reported to enhance the malignant properties of cancer cells. In fact, GD2-positive (GD2+) cells showed increased proliferation, invasion, and adhesion, compared with GD2-negative (GD2-) cells. However, the precise mechanisms by which gangliosides regulate cell signaling in GEM/rafts are not well understood. In order to analyze the roles of ganglioside GD2 in the malignant properties of melanoma cells, we searched for GD2-associating molecules on the cell membrane using the enzyme-mediated activation of radical sources combined with mass spectrometry, and integrin β1 was identified as a representative GD2-associating molecule. Then, we showed the physical association of GD2 and integrin β1 by immunoprecipitation/immunoblotting. Close localization was also shown by immuno-cytostaining and the proximity ligation assay. During cell adhesion, GD2+ cells showed multiple phospho-tyrosine bands, i.e., the epithelial growth factor receptor and focal adhesion kinase. The knockdown of integrin β1 revealed that the increased malignant phenotypes in GD2+ cells were clearly cancelled. Furthermore, the phosphor-tyrosine bands detected during the adhesion of GD2+ cells almost completely disappeared after the knockdown of integrin β1. Finally, immunoblotting to examine the intracellular distribution of integrins during cell adhesion revealed that large amounts of integrin β1 were localized in GEM/raft fractions in GD2+ cells before and just after cell adhesion, with the majority being localized in the non-raft fractions in GD2- cells. All these results suggest that GD2 and integrin β1 cooperate in GEM/rafts, leading to enhanced malignant phenotypes of melanomas.
Identifiants
pubmed: 35008849
pii: ijms23010423
doi: 10.3390/ijms23010423
pmc: PMC8745508
pii:
doi:
Substances chimiques
Antibodies, Monoclonal
0
Collagen Type I
0
Gangliosides
0
Integrin beta1
0
Integrins
0
Phosphotyrosine
21820-51-9
ganglioside, GD2
65988-71-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Ministry of Education, Culture, Sports and Technology of Japan
ID : 15H04696, 17K19616, 18H02628, 19K22518, 21K06828, 21H026
Organisme : JST-CREST
ID : JPMJCR17H2
Références
Cancer Res. 1996 Jun 15;56(12):2844-8
pubmed: 8665524
Neuroscience. 2019 Jan 15;397:94-106
pubmed: 30521973
Cancer Sci. 2018 Jan;109(1):141-153
pubmed: 29151270
Immunotherapy. 2016 Sep;8(9):1097-117
pubmed: 27485082
J Biol Chem. 1992 Jun 15;267(17):12082-9
pubmed: 1601877
Glycobiology. 2012 Jun;22(6):806-16
pubmed: 22301273
Biochim Biophys Acta. 2008 Mar;1780(3):325-46
pubmed: 17976918
Proc Natl Acad Sci U S A. 1985 Feb;82(4):1242-6
pubmed: 3883355
Int J Mol Sci. 2020 Mar 11;21(6):
pubmed: 32168753
FEBS Lett. 1986 Nov 10;208(1):17-22
pubmed: 3533633
PLoS One. 2018 Nov 21;13(11):e0206881
pubmed: 30462668
J Invest Dermatol. 1996 Oct;107(4):543-8
pubmed: 8823358
Proc Natl Acad Sci U S A. 1986 Nov;83(22):8694-8
pubmed: 3464977
J Neurooncol. 2020 May;147(3):577-585
pubmed: 32246395
J Biol Chem. 1999 May 14;274(20):13744-7
pubmed: 10318776
Oncoimmunology. 2015 May 22;4(7):e1016704
pubmed: 26140243
Proc Natl Acad Sci U S A. 1985 Aug;82(15):5155-9
pubmed: 3860849
Cancer Res. 1989 Jul 1;49(13):3445-51
pubmed: 2471585
Cancer Sci. 2012 Sep;103(9):1656-64
pubmed: 22632091
Oncotarget. 2017 Sep 16;8(56):95620-95631
pubmed: 29221154
J Clin Invest. 2012 Jun;122(6):2066-78
pubmed: 22585577
Chembiochem. 2017 Jul 4;18(13):1146-1154
pubmed: 28295942
An Acad Bras Cienc. 2004 Sep;76(3):553-72
pubmed: 15334254
J Biochem. 2020 Aug 1;168(2):103-112
pubmed: 32282910
Exp Mol Pathol. 2019 Aug;109:25-35
pubmed: 31075227
Cancer Res. 1987 Mar 15;47(6):1724-30
pubmed: 3493067
Cancer Res. 1985 Jun;45(6):2642-9
pubmed: 2580625
J Virol. 2008 Sep;82(17):8349-61
pubmed: 18562515
Proc Natl Acad Sci U S A. 1984 Sep;81(18):5767-71
pubmed: 6385004
Cancer. 1992 Aug 1;70(3):633-8
pubmed: 1623478
Cancer Res. 1984 Nov;44(11):5262-5
pubmed: 6488184
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10455-9
pubmed: 7937974
Oncogene. 2015 Jun 4;34(23):2958-67
pubmed: 25109336
Curr Opin Hematol. 2003 Jan;10(1):16-24
pubmed: 12483107
Front Oncol. 2020 Jul 07;10:1000
pubmed: 32733795
Ann N Y Acad Sci. 2021 Oct 1;:
pubmed: 34596246
Oncoimmunology. 2019 Nov 7;9(1):1683345
pubmed: 32002293
J Biol Chem. 2010 Aug 27;285(35):27213-27223
pubmed: 20581115
J Biol Chem. 2016 Aug 5;291(32):16630-43
pubmed: 27288875
Oncogene. 2005 Jul 14;24(30):4754-64
pubmed: 15870699
Biochim Biophys Acta Gen Subj. 2017 Oct;1861(10):2479-2484
pubmed: 28602513
J Biol Chem. 2015 Jun 26;290(26):16043-58
pubmed: 25940087
Cancer Sci. 2019 May;110(5):1544-1551
pubmed: 30895683
Proteomics. 2012 Nov;12(21):3154-63
pubmed: 22936677
Glycobiology. 2016 Sep;26(9):984-998
pubmed: 27102283
Prog Brain Res. 1994;101:119-26
pubmed: 8029445
Nat Med. 2018 May;24(5):572-579
pubmed: 29662203
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7405-9
pubmed: 18495923
Glycoconj J. 2012 Dec;29(8-9):579-84
pubmed: 22763744
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33722905
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1972-6
pubmed: 8095337
J Neurochem. 2011 Mar;116(5):690-5
pubmed: 21214558